Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Phytother Res ; 32(12): 2376-2388, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30281175

ABSTRACT

Beta (ß)-caryophyllene (BCAR) is a major sesquiterpene of various plant essential oils reported for several important pharmacological activities, including antioxidant, anti-inflammatory, anticancer, cardioprotective, hepatoprotective, gastroprotective, nephroprotective, antimicrobial, and immune-modulatory activity. Recent studies suggest that it also possesses neuroprotective effect. This study reviews published reports pertaining to the neuropharmacological activities of BCAR. Databases such as PubMed, Scopus, MedLine Plus, and Google Scholar with keywords "beta (ß)-caryophyllene" and other neurological keywords were searched. Data were extracted by referring to articles with information about the dose or concentration/route of administration, test system, results and discussion, and proposed mechanism of action. A total of 545 research articles were recorded, and 41 experimental studies were included in this review, after application of exclusion criterion. Search results suggest that BCAR exhibits a protective role in a number of nervous system-related disorders including pain, anxiety, spasm, convulsion, depression, alcoholism, and Alzheimer's disease. Additionally, BCAR has local anesthetic-like activity, which could protect the nervous system from oxidative stress and inflammation and can act as an immunomodulatory agent. Most neurological activities of this natural product have been linked with the cannabinoid receptors (CBRs), especially the CB2R. This review suggests a possible application of BCAR as a neuroprotective agent.


Subject(s)
Neuroprotective Agents/pharmacology , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Animals , Biological Products/therapeutic use , Central Nervous System Agents/pharmacology , Central Nervous System Agents/therapeutic use , Central Nervous System Diseases/drug therapy , Central Nervous System Diseases/prevention & control , Humans , Neuroprotective Agents/therapeutic use , Oils, Volatile/therapeutic use , Phytotherapy/methods , Plant Extracts/therapeutic use , Polycyclic Sesquiterpenes , Sesquiterpenes/therapeutic use
3.
Chemosphere ; 204: 220-226, 2018 08.
Article in English | MEDLINE | ID: mdl-29656158

ABSTRACT

Omeprazole (OME) is a proton pump inhibitor used for the treatment of various gastric and intestinal disease; however, studies on its effects on the genetic materials are still restricted. The present study aimed to evaluate possible toxicogenic effects of OME in Allium cepa meristems with the application of cytogenetic biomarkers for DNA damage, mutagenic, toxic and cytotoxic effects. Additionally, retinol palmitate (RP) and ascorbic acid (AA) were also co-treated with OME to evaluate possible modulatory effects of OME-induced cytogenetic damages. OME was tested at 10, 20 and 40 µg/mL, while RP and AA at 55 µg/mL and 352.2 µg/mL, respectively. Copper sulphate (0.6 µg/mL) and dechlorinated water were used as positive control and negative control, respectively. The results suggest that OME induced genotoxicity and mutagenicity in A. cepa at all tested concentrations. It was noted that cotreatment of OME with the antioxidant vitamins RP and/or AA significantly (p < 0.05) inhibited and/or modulated all toxicogenic damages induced by OME. These observations demonstrate their antigenotoxic, antimutagenic, antitoxic and anticitotoxic effects in A. cepa. This study indicates that application of antioxidants may be useful tools to overcome OME-induced toxic effects.


Subject(s)
Allium/drug effects , Ascorbic Acid/pharmacology , Omeprazole/toxicity , Toxicogenetics/methods , Vitamin A/analogs & derivatives , Antioxidants/pharmacology , DNA Damage/drug effects , Diterpenes , Mutagenesis/drug effects , Mutagens , Plant Extracts/pharmacology , Retinyl Esters , Vitamin A/pharmacology
4.
IUBMB Life ; 70(5): 420-431, 2018 05.
Article in English | MEDLINE | ID: mdl-29573147

ABSTRACT

Antianxiety drugs currently in use are associated with a number of serious side effects. Present study was designed to evaluate the efficacy of anacardic acids (AAs) isolated from cashew nut (Anacardium occidentale L.) shell liquid (CNSL) to treat anxiety as well as its role in oxidative stress in mice model. Anxiolytic effect of AA was evaluated using rota-rod and a set of behavioral tests in male Swiss albino mice at the doses of 10, 25, and 50 mg/kg. Flumazenil was used to evaluate the possible involvement of GABAergic system in the mechanism of action of AA. The effect of AA on oxidative stress in mice was evaluated by determining the concentration of malondialdehyde (MDA), reduced glutathione, and catalase (CAT) activity. The detection of DNA damage of the treated animals was performed using alkaline comet test in the hippocampus and frontal cortex of the animals. The results demonstrated that AA did not produce myorelaxant and sedative effects, nor did it cause a decrease in locomotor activity. The anxiolytic effect of AA was well-evident in all tests, especially at higher dose levels (25 and 50 mg/mg). Flumazenil reversed the anxiolytic effect of AA at all doses. In addition, AA reduced oxidative stress by decreasing the concentration of MDA and increasing the levels of reduced glutathione (GSH) and CAT activity. Statistical analysis by Pearson's correlation indicated a positive correlation between anxiolytic effect of AA to its antioxidant and lipid peroxidation inhibitory activity. Furthermore, increased CAT activity and GSH concentrations in the hippocampus and frontal cortex of mice was also complementary to the reduced genotoxic damage observed in the study. In comet assay, AA did not increase in DNA damage. In conclusion, the results supported that AA possesses GABAA receptor mediated anxiolytic activity with the lack of myorelaxation and genotoxicity. © 2018 IUBMB Life, 70(5):420-431, 2018.


Subject(s)
Anacardic Acids/pharmacology , Anacardium/chemistry , Anti-Anxiety Agents/pharmacology , Antioxidants/pharmacology , Anxiety/drug therapy , Anacardic Acids/chemistry , Anacardic Acids/isolation & purification , Animals , Anti-Anxiety Agents/chemistry , Anti-Anxiety Agents/isolation & purification , Antioxidants/chemistry , Antioxidants/isolation & purification , Anxiety/metabolism , Anxiety/physiopathology , Catalase/metabolism , Diazepam/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Glutathione/metabolism , Male , Maze Learning , Mice , Mice, Inbred ICR , Nuts/chemistry , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Plant Extracts/chemistry , Rotarod Performance Test
5.
PLoS Negl Trop Dis ; 9(4): e0003699, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25837313

ABSTRACT

BACKGROUND: Bangladesh is one of the endemic countries for Visceral Leishmaniasis (VL). Médecins Sans Frontières (MSF) ran a VL treatment clinic in the most endemic district (Fulbaria) between 2010 and 2013 using a semi-ambulatory regimen for primary VL of 15 mg/kg Liposomal Amphotericin-B (AmBisome) in three equal doses of 5 mg/kg. The main objective of this study was to analyze the effectiveness and safety of this regimen after a 12 month follow-up period by retrospective analysis of routinely collected program data. A secondary objective was to explore risk factors for relapse. METHODS AND PRINCIPAL FINDINGS: Our analysis included 1521 patients who were initially cured, of whom 1278 (84%) and 1179 (77.5%) were followed-up at 6 and 12 months, respectively. Cure rates at 6 and 12 months were 98.7% (1262/1278) and 96.4% (1137/1179), respectively. Most relapses (26/39) occurred between 6 and 12 months after treatment. Serious adverse events (SAE) were recorded for 7 patients (0.5%). Odds of relapse at 12 months were highest in the youngest and oldest age groups. There was some evidence that spleen size measured on discharge (one month after initiation of treatment) was associated with risk of relapse: OR=1.25 (95% CI 1.01 to 1.55) per cm below lower costal margin (P=0.04). CONCLUSIONS: Our study demonstrates that 15 mg/kg AmBisome in three doses of 5 mg/kg is an effective (>95% cure rate) and safe (<1% SAE) treatment for primary VL in Bangladesh. The majority of relapses occurred between 6 and 12 months, justifying the use of a longer follow-up period when feasible. Assessment of risk of relapse based on easily measured clinical parameters such as spleen size could be incorporated in VL treatment protocols in resource-poor settings where test-of-cure is not always feasible.


Subject(s)
Amphotericin B/therapeutic use , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/epidemiology , Adolescent , Adult , Bangladesh/epidemiology , Female , Humans , Male , Middle Aged , Recurrence , Retrospective Studies , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL